Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 112 articles:
HTML format
Text format



Single Articles


    May 2017
  1. ALDOSS I, Song J, Stiller T, Nguyen T, et al
    Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia.
    Am J Hematol. 2017 May 11. doi: 10.1002/ajh.24783.
    PubMed     Text format     Abstract available


  2. RAGON BK, Daver N, Garcia-Manero G, Ravandi F, et al
    Minimal Residual Disease Eradication with Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia.
    Am J Hematol. 2017 May 11. doi: 10.1002/ajh.24782.
    PubMed     Text format     Abstract available


  3. GONCALVES MV, Rodrigues CA, Metze IGHL, Lacerda MP, et al
    Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases.
    Am J Hematol. 2017 May 5. doi: 10.1002/ajh.24779.
    PubMed     Text format    


  4. NANAH R, McCullough K, Hogan W, Begna K, et al
    Outcome of Elderly Patients after Failure to Hypomethylating Agents Given as Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience.
    Am J Hematol. 2017 May 5. doi: 10.1002/ajh.24780.
    PubMed     Text format     Abstract available


  5. CASTAGNETTI F, Gugliotta G, Breccia M, Iurlo A, et al
    The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Am J Hematol. 2017 May 2. doi: 10.1002/ajh.24774.
    PubMed     Text format     Abstract available



  6. Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.
    Am J Hematol. 2017;92:E85.
    PubMed     Text format    


    April 2017
  7. CANAANI J, Savani BN, Labopin M, Michallet M, et al
    ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia - a report from the acute leukemia working party of the EBMT.
    Am J Hematol. 2017 Apr 25. doi: 10.1002/ajh.24771.
    PubMed     Text format     Abstract available


  8. BHATT VR, Shostrom V, Giri S, Gundabolu K, et al
    Early Mortality and Overall Survival of Acute Myeloid Leukemia Based on Facility Type.
    Am J Hematol. 2017 Apr 24. doi: 10.1002/ajh.24767.
    PubMed     Text format     Abstract available


  9. LARSEN JT, Shanafelt TD, Leis JF, LaPlant B, et al
    Akt inhibitor MK-2206 in combination with Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the N1087 Alliance Study.
    Am J Hematol. 2017 Apr 12. doi: 10.1002/ajh.24762.
    PubMed     Text format     Abstract available


  10. BAPTISTA MJ, Granada I, Morgades M, Calasanz MJ, et al
    Monosomal karyotype in chronic lymphocytic leukemia: association with clinical and biological features and potential prognostic significance.
    Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24754.
    PubMed     Text format    


  11. REDA G, Cassin R, Fattizzo B, Giannarelli D, et al
    Chronic lymphocytic leukemia (CLL) and prognostic models: A bridge between clinical and biological markers.
    Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24755.
    PubMed     Text format    


  12. SACHA T, Gora-Tybor J, Szarejko M, Bober G, et al
    A multicenter prospective study on efficacy and safety of imatinib generics; a report from Polish Adult Leukemia Group imatinib generics registry.
    Am J Hematol. 2017 Apr 4. doi: 10.1002/ajh.24748.
    PubMed     Text format     Abstract available


    March 2017
  13. WEINBERG OK, Gibson CJ, Blonquist TM, Neuberg D, et al
    NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO Classification.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24739.
    PubMed     Text format    


  14. CANAANI J, Labopin M, Socie G, Nihtinen A, et al
    Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the EBMT.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24737.
    PubMed     Text format     Abstract available


  15. KANTARJIAN HM, Schuster MW, Jain N, Advani A, et al
    A Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients With Acute Myeloid Leukemia.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24736.
    PubMed     Text format     Abstract available


  16. ALFONSO A, Montalban-Bravo G, Takahashi K, Jabbour EJ, et al
    Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24735.
    PubMed     Text format     Abstract available


  17. KANDARPA M, Wu YM, Robinson D, Burke PW, et al
    Clinical Characteristics and Whole Exome/Transcriptome Sequencing of Coexisting Chronic Myeloid Leukemia and Myelofibrosis.
    Am J Hematol. 2017 Mar 23. doi: 10.1002/ajh.24728.
    PubMed     Text format     Abstract available


  18. PATNAIK MM, Barraco D, Lasho TL, Finke CM, et al
    Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.
    Am J Hematol. 2017 Mar 17. doi: 10.1002/ajh.24722.
    PubMed     Text format     Abstract available


  19. SHORT NJ, Kantarjian HM, Ko H, Khoury JD, et al
    Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
    Am J Hematol. 2017 Mar 15. doi: 10.1002/ajh.24720.
    PubMed     Text format    


  20. MAURO FR, Galieni P, Tedeschi A, Laurenti L, et al
    Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
    Am J Hematol. 2017 Mar 10. doi: 10.1002/ajh.24714.
    PubMed     Text format     Abstract available


  21. MICHALLET AS, Campidelli A, Lequeu H, Dilhuydy MS, et al
    Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France A study from the French Innovative Leukemia Organization (FILO) group.
    Am J Hematol. 2017 Mar 10. doi: 10.1002/ajh.24715.
    PubMed     Text format    


    February 2017
  22. KAYA Z, Alici N, Ozmen OE, Akgul M, et al
    Identification of renal infiltration based on urinary findings in a child with burkitt leukemia/lymphoma.
    Am J Hematol. 2017 Feb 22. doi: 10.1002/ajh.24694.
    PubMed     Text format    


  23. DE MARCHI F, Candoni A, Zannier ME, Lau WY, et al
    Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD Acute Myeloid Leukemia patients: which should we trust as a minimal residual disease marker?
    Am J Hematol. 2017 Feb 17. doi: 10.1002/ajh.24686.
    PubMed     Text format    


  24. HU Z, Medeiros LJ, Fang L, Sun Y, et al
    Prognostic Significance of Cytogenetic Abnormalities in T-Cell Prolymphocytic Leukemia.
    Am J Hematol. 2017 Feb 14. doi: 10.1002/ajh.24679.
    PubMed     Text format     Abstract available


  25. USTUN C, Williams S, Skendzel S, Kodal B, et al
    Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia.
    Am J Hematol. 2017 Feb 10. doi: 10.1002/ajh.24673.
    PubMed     Text format    


  26. BORATE U, Norris BA, Lo P, Tognon C, et al
    Identification of targeted therapies for rare adult mature t-cell leukemia using functional ex vivo screening of primary patient samples.
    Am J Hematol. 2017 Feb 9. doi: 10.1002/ajh.24669.
    PubMed     Text format    


  27. SHOUVAL R, Bonifazi F, Fein J, Boschini C, et al
    Validation of the Acute Leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort.
    Am J Hematol. 2017 Feb 9. doi: 10.1002/ajh.24677.
    PubMed     Text format     Abstract available


    January 2017
  28. JENTZSCH M, Bill M, Nicolet D, Leiblein S, et al
    Prognostic Impact of the CD34+/CD38- Cell Burden in Patients with Acute Myeloid Leukemia receiving Allogeneic Stem Cell Transplantation.
    Am J Hematol. 2017 Jan 30. doi: 10.1002/ajh.24663.
    PubMed     Text format     Abstract available


  29. DELGADO J, Doubek M, Baumann T, Kotaskova J, et al
    Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
    Am J Hematol. 2017 Jan 25. doi: 10.1002/ajh.24660.
    PubMed     Text format     Abstract available


  30. JAYAKAR V, Cheung K, Yebra-Fernandez E, Bain BJ, et al
    The distinctive cytological features of T-cell prolymphocytic leukemia.
    Am J Hematol. 2017 Jan 25. doi: 10.1002/ajh.24659.
    PubMed     Text format    


  31. PLUTA A, Robak T, Wrzesien-Kus A, Budziszewska BK, et al
    Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly AML patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
    Am J Hematol. 2017 Jan 19. doi: 10.1002/ajh.24654.
    PubMed     Text format     Abstract available


  32. FUJISAWA S, Mizuta S, Akiyama H, Ueda Y, et al
    Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
    Am J Hematol. 2017 Jan 19. doi: 10.1002/ajh.24653.
    PubMed     Text format     Abstract available


  33. TIRIBELLI M, Geromin A, Damiani D
    Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia.
    Am J Hematol. 2017 Jan 11. doi: 10.1002/ajh.24651.
    PubMed     Text format    


  34. WEINBERG OK, Sohani AR, Bhargava P, Nardi V, et al
    Diagnostic Work-up of Acute Myeloid Leukemia.
    Am J Hematol. 2017 Jan 9. doi: 10.1002/ajh.24648.
    PubMed     Text format     Abstract available


  35. GABALLA S, Saliba R, Oran B, Brammer JE, et al
    Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation.
    Am J Hematol. 2017 Jan 4. doi: 10.1002/ajh.24632.
    PubMed     Text format     Abstract available


  36. PEMMARAJU N, Kantarjian H, Jorgensen JL, Jabbour E, et al
    Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
    Am J Hematol. 2017 Jan 4. doi: 10.1002/ajh.24629.
    PubMed     Text format     Abstract available


  37. CANAANI J, Beohou E, Labopin M, Socie G, et al
    Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT.
    Am J Hematol. 2017 Jan 4. doi: 10.1002/ajh.24640.
    PubMed     Text format     Abstract available


    December 2016
  38. WANG W, Wang SA, Medeiros LJ, Khoury JD, et al
    Pure Erythroid Leukemia.
    Am J Hematol. 2016 Dec 22. doi: 10.1002/ajh.24626.
    PubMed     Text format     Abstract available


  39. SHORT NJ, Kantarjian HM, Sasaki K, Ravandi F, et al
    Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
    Am J Hematol. 2016 Dec 22. doi: 10.1002/ajh.24625.
    PubMed     Text format     Abstract available


    November 2016
  40. PINNIX CC, Chi L, Jabbour EJ, Milgrom SA, et al
    Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia.
    Am J Hematol. 2016 Nov 22. doi: 10.1002/ajh.24611.
    PubMed     Text format     Abstract available


  41. ALDOSS I, Stiller T, Song J, AlMalki M, et al
    Philadelphia chromosome as a recurrent event among therapy-related acute leukemia.
    Am J Hematol. 2016 Nov 10. doi: 10.1002/ajh.24604.
    PubMed     Text format    


  42. WINESTONE LE, Getz KD, Miller TP, Wilkes JJ, et al
    The Role of Acuity of Illness at Presentation in Early Mortality in Black Children with Acute Myeloid Leukemia.
    Am J Hematol. 2016 Nov 10. doi: 10.1002/ajh.24605.
    PubMed     Text format     Abstract available


  43. BAIN BJ
    Early leukemic transformation of adult T-cell leukemia/lymphoma presenting as meningeal lymphoma.
    Am J Hematol. 2016 Nov 8. doi: 10.1002/ajh.24602.
    PubMed     Text format    


  44. SAYAR H, Bashardoust P, Cripe L, Chakraborty S, et al
    Long-term outcome of NPM1 mutated acute myeloid leukemia: A single-institution experience.
    Am J Hematol. 2016 Nov 4. doi: 10.1002/ajh.24601.
    PubMed     Text format    


    October 2016
  45. CASTAGNETTI F, Di Raimondo F, De Vivo A, Spitaleri A, et al
    A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
    Am J Hematol. 2016 Oct 22. doi: 10.1002/ajh.24591.
    PubMed     Text format     Abstract available


  46. NABHAN C, Mato AR, Feinberg BA
    Clinical Pathways in Chronic lymphocytic Leukemia: Challenges and Solutions.
    Am J Hematol. 2016 Oct 20. doi: 10.1002/ajh.24589.
    PubMed     Text format    


  47. RAESS PW, Cascio MJ, Fan G, Press R, et al
    Concurrent STAT3, DNMT3A and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential.
    Am J Hematol. 2016 Oct 19. doi: 10.1002/ajh.24586.
    PubMed     Text format    


  48. GREENER D, Henrichs KF, Liesveld JL, Heal JM, et al
    Improved Outcomes in Acute Myeloid Leukemia Patients Treated with Washed Transfusions.
    Am J Hematol. 2016 Oct 19. doi: 10.1002/ajh.24585.
    PubMed     Text format    


  49. PATNAIK MM, Barraco D, Lasho TL, Finke CM, et al
    DNMT3A Mutations are Associated with Inferior Overall and Leukemia-free Survival in Chronic Myelomonocytic Leukemia.
    Am J Hematol. 2016 Oct 12. doi: 10.1002/ajh.24581.
    PubMed     Text format     Abstract available


  50. HU Z, Sun Y, Wang W, Medeiros LJ, et al
    Refractory Hairy Cell Leukemia-Variant.
    Am J Hematol. 2016 Oct 11. doi: 10.1002/ajh.24580.
    PubMed     Text format    


  51. ROSKO A, Wang HL, de Lima M, Sandmaier B, et al
    Reduced Intensity Conditioned Allograft Yields Favorable Survival for Older Adults with B-cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2016 Oct 6. doi: 10.1002/ajh.24575.
    PubMed     Text format     Abstract available


    September 2016
  52. LI R, Hu X, Wang L, Cheng H, et al
    Fludarabine and Cytarabine versus High-dose Cytarabine in Consolidation Treatment of t(8; 21) Acute Myeloid Leukemia: a prospective, randomized study.
    Am J Hematol. 2016 Sep 27. doi: 10.1002/ajh.24569.
    PubMed     Text format     Abstract available


  53. EDER S, Beohou E, Labopin M, Sanz J, et al
    Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia - a survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Am J Hematol. 2016 Sep 27. doi: 10.1002/ajh.24567.
    PubMed     Text format     Abstract available



  54. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia.
    Am J Hematol. 2016;91:965.
    PubMed     Text format    


    August 2016
  55. CORTES JE, Khoury HJ, Kantarjian HM, Lipton JH, et al
    Long-term Bosutinib For Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib Plus Dasatinib and/or Nilotinib.
    Am J Hematol. 2016 Aug 17. doi: 10.1002/ajh.24536.
    PubMed     Text format     Abstract available


  56. ESTEY E
    Acute myeloid leukemia: 2016 Update on risk-stratification and management.
    Am J Hematol. 2016;91:824-46.
    PubMed     Text format     Abstract available


    July 2016
  57. KUMAR AJ, Gimotty PA, Gelfand J, Buck G, et al
    Delays in Post-Remission Chemotherapy for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia are Associated with Inferior Outcomes in Patients who Undergo Allogeneic Transplant: An Analysis from ECOG 2993/MRC UK ALLXII.
    Am J Hematol. 2016 Jul 28. doi: 10.1002/ajh.24497.
    PubMed     Text format     Abstract available


  58. JAIN P, Kanagal-Shamanna R, Wierda W, Keating M, et al
    Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia.
    Am J Hematol. 2016 Jul 28. doi: 10.1002/ajh.24496.
    PubMed     Text format    


  59. MOLICA S, Shanafelt TD, Giannarelli D, Gentile M, et al
    The chronic lymphocytic leukemia international prognostic index (CLL-IPI) predicts time to first treatment in early CLL: Independent Validation in a Prospective Cohort of Early Stage Patients.
    Am J Hematol. 2016 Jul 27. doi: 10.1002/ajh.24493.
    PubMed     Text format     Abstract available


  60. AGBAY RL, Jain N, Loghavi S, Medeiros LJ, et al
    Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Am J Hematol. 2016 Jul 14. doi: 10.1002/ajh.24473.
    PubMed     Text format     Abstract available


  61. FLINN IW, Ruppert AS, Harwin W, Waterhouse D, et al
    A Phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia (CLL).
    Am J Hematol. 2016 Jul 7. doi: 10.1002/ajh.24468.
    PubMed     Text format     Abstract available


    June 2016
  62. DUBUC AM, Davids MS, Pulluqi M, Pulluqi O, et al
    FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated Chronic Lymphocytic Leukemia (CLL).
    Am J Hematol. 2016 Jun 24. doi: 10.1002/ajh.24452.
    PubMed     Text format     Abstract available


  63. PATNAIK MM, Tefferi A
    Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.
    Am J Hematol. 2016;91:631-42.
    PubMed     Text format     Abstract available


  64. KUMAR AJ, Vassilev P, Loren AW, Luger SM, et al
    Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.
    Am J Hematol. 2016;91:426-9.
    PubMed     Text format     Abstract available


  65. HAMILTON BK, Visconte V, Jia X, Tabarroki A, et al
    Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
    Am J Hematol. 2016;91:406-9.
    PubMed     Text format     Abstract available


  66. CUNNINGHAM I, Kohno B
    18 FDG-PET/CT: 21st century approach to leukemic tumors in 124 cases.
    Am J Hematol. 2016;91:379-84.
    PubMed     Text format     Abstract available


    May 2016
  67. SHAH NP, Rousselot P, Schiffer C, Rea D, et al
    Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
    Am J Hematol. 2016 May 19. doi: 10.1002/ajh.24423.
    PubMed     Text format     Abstract available


  68. RYTTING ME, Jabbour EJ, Jorgensen JL, Ravandi F, et al
    Final results of a single institution experience with a pediatric-based regimen, the augmented berlin-frankfurt-munster (ABFM), in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL), and comparison to the hyper-CVAD regimen.
    Am J Hematol. 2016 May 14. doi: 10.1002/ajh.24419.
    PubMed     Text format     Abstract available


  69. BADAR T, Handisides DR, Benito JM, Richie MA, et al
    A Phase I Study of Evofosfamide, an Investigational Hypoxia-Activated Prodrug, in Patients with Advanced Leukemia.
    Am J Hematol. 2016 May 11. doi: 10.1002/ajh.24415.
    PubMed     Text format     Abstract available


  70. WOLACH O, Stevenson KE, Wadleigh M, DeAngelo DJ, et al
    Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission.
    Am J Hematol. 2016 May 6. doi: 10.1002/ajh.24410.
    PubMed     Text format     Abstract available



  71. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).
    Am J Hematol. 2016;91:E301.
    PubMed     Text format    


  72. KONUMA T, Tsukada N, Kanda J, Uchida N, et al
    Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older.
    Am J Hematol. 2016;91:E284-92.
    PubMed     Text format     Abstract available


  73. ELALA YC, Lasho TL, Gangat N, Finke C, et al
    Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
    Am J Hematol. 2016;91:503-6.
    PubMed     Text format     Abstract available


  74. KOMROKJI RS, Kulasekararaj A, Al Ali NH, Kordasti S, et al
    Autoimmune diseases and myelodysplastic syndromes.
    Am J Hematol. 2016;91:E280-3.
    PubMed     Text format     Abstract available


  75. CEPPI F, Weitzman S, Woessmann W, Davies K, et al
    Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
    Am J Hematol. 2016;91:486-91.
    PubMed     Text format     Abstract available


  76. HEXNER EO, Luger SM, Reshef R, Jeschke GR, et al
    Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment.
    Am J Hematol. 2016;91:453-60.
    PubMed     Text format     Abstract available


    April 2016
  77. EGAN D, Radich J
    Monitoring Disease Burden in Chronic Myeloid Leukemia: Past, Present, and Future.
    Am J Hematol. 2016 Apr 5. doi: 10.1002/ajh.24381.
    PubMed     Text format     Abstract available


  78. FRIEDMAN DR, Sibley AB, Owzar K, Chaffee KG, et al
    Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: A multi-institutional study.
    Am J Hematol. 2016 Apr 2. doi: 10.1002/ajh.24376.
    PubMed     Text format     Abstract available


    March 2016
  79. NABHAN C, Chaffee KG, Slager SL, Galanina N, et al
    Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia.
    Am J Hematol. 2016 Mar 25. doi: 10.1002/ajh.24374.
    PubMed     Text format     Abstract available


  80. GUGLIOTTA G, Castagnetti F, Breccia M, Gozzini A, et al
    Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.
    Am J Hematol. 2016 Mar 11. doi: 10.1002/ajh.24362.
    PubMed     Text format     Abstract available


  81. CHANTEPIE SP, Parienti JJ, Salaun V, Benabed K, et al
    The prognostic value of hematogones in patients with acute myeloid leukemia.
    Am J Hematol. 2016 Mar 2. doi: 10.1002/ajh.24350.
    PubMed     Text format     Abstract available


  82. BERNARDI M, Carrabba M, Messina C, Milani R, et al
    Elderly patients > 65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs.
    Am J Hematol. 2016 Mar 1. doi: 10.1002/ajh.24345.
    PubMed     Text format    


  83. SEFTEL MD, Neuberg D, Zhang MJ, Wang HL, et al
    Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.
    Am J Hematol. 2016;91:322-9.
    PubMed     Text format     Abstract available


  84. PATNAIK MM, Lasho TL, Finke CM, Pardanani A, et al
    Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis.
    Am J Hematol. 2016;91:E12-4.
    PubMed     Text format    


  85. DEOTARE U, Yee KW, Le LW, Porwit A, et al
    Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy.
    Am J Hematol. 2016;91:283-6.
    PubMed     Text format     Abstract available


    February 2016
  86. PANERO J, Alves-Paiva RM, Roisman A, Santana-Lemos BA, et al
    Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
    Am J Hematol. 2016 Feb 6. doi: 10.1002/ajh.24324.
    PubMed     Text format     Abstract available


  87. JABBOUR E, Kantarjian H
    Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Am J Hematol. 2016;91:252-265.
    PubMed     Text format     Abstract available


  88. DINARDO CD, Garcia-Manero G, Pierce S, Nazha A, et al
    Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Am J Hematol. 2016;91:227-232.
    PubMed     Text format     Abstract available


  89. TAVITIAN S, Denis A, Vergez F, Berard E, et al
    Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy.
    Am J Hematol. 2016;91:193-8.
    PubMed     Text format     Abstract available


    January 2016
  90. BERNASCONI P, Farina M, Boni M, Dambruoso I, et al
    Therapeutically targeting self-reinforcing leukemic niches in acute myeloid leukemia (AML): A worthy endeavour?
    Am J Hematol. 2016 Jan 28. doi: 10.1002/ajh.24312.
    PubMed     Text format     Abstract available


  91. ROOS-WEIL D, Nguyen-Khac F, Bernard OA
    Chronic lymphocytic leukemia: Time to go past genomics?
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24301.
    PubMed     Text format     Abstract available


  92. WU B, Harrison G, Wang E
    "Hairy" cells in acute promyelocytic leukemia: Excess myeloperoxidase with formation of needle-shaped crystalline projections on the cytochemical stain in a case with variant morphology.
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24298.
    PubMed     Text format    


  93. SALE S, Fumi M, Pancione Y, Parente D, et al
    The fortuitous diagnosis of Burkitt lymphoma in a patient with chronic myelomonocytic leukemia.
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24297.
    PubMed     Text format    


  94. VITALE C, Jabbour E, Lu X, Yabe M, et al
    Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia.
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24302.
    PubMed     Text format    


  95. SHORT NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, et al
    Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.
    Am J Hematol. 2016 Jan 21. doi: 10.1002/ajh.24296.
    PubMed     Text format     Abstract available


  96. JAIN P, Tang G, Huh YO, Yin CC, et al
    Philadelphia - positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation.
    Am J Hematol. 2016 Jan 21. doi: 10.1002/ajh.24295.
    PubMed     Text format    


  97. FORDHAM NJ, Stern S, Swansbury J, Bain BJ, et al
    The distinctive micromegakaryocytes of transformed chronic myeloid leukemia.
    Am J Hematol. 2016 Jan 9. doi: 10.1002/ajh.24290.
    PubMed     Text format    


  98. JABBOUR E
    Chronic myeloid leukemia: First-line drug of choice.
    Am J Hematol. 2016;91:59-66.
    PubMed     Text format     Abstract available


  99. FREY NV, Porter DL
    CAR T-cells merge into the fast lane of cancer care.
    Am J Hematol. 2016;91:146-50.
    PubMed     Text format     Abstract available


  100. TEFFERI A
    Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
    Am J Hematol. 2016;91:50-8.
    PubMed     Text format     Abstract available


    December 2015
  101. MANGARU Z, Shetty S, Visconte V, Liu HD, et al
    Acute myeloid leukemia with inv(16)(p13.1q22), abnormal eosinophils, and absence of peripheral blood and bone marrow blasts.
    Am J Hematol. 2015 Dec 30. doi: 10.1002/ajh.24289.
    PubMed     Text format    


  102. ELLIOTT MA, Tefferi A
    Chronic Neutrophilic Leukemia 2016: Update on diagnosis, molecular genetics, prognosis and management.
    Am J Hematol. 2015 Dec 23. doi: 10.1002/ajh.24284.
    PubMed     Text format     Abstract available


  103. RAI KR, Jain P
    Chronic lymphocytic leukemia (CLL) - Then and Now.
    Am J Hematol. 2015 Dec 21. doi: 10.1002/ajh.24282.
    PubMed     Text format     Abstract available


  104. CAMPUZANO-ZULUAGA G, Deutsch Y, Salzberg M, Gomez A, et al
    Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24271.
    PubMed     Text format     Abstract available


  105. AOKI J, Kanamori H, Tanaka M, Yamasaki S, et al
    Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia.
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24270.
    PubMed     Text format     Abstract available


  106. YU H, Wertheim G, Shankar S, Paessler M, et al
    Marked eosinophilia masking B lymphoblastic leukemia.
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24266.
    PubMed     Text format    


  107. ZENT CS, Wang XV, Ketterling RP, Hanson CA, et al
    A Phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: A Trial of the ECOG-ACRIN Cancer Research Group (E1908).
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24265.
    PubMed     Text format     Abstract available


  108. MOLLER T, Moser C, Adamsen L, Rugaard G, et al
    Early warning and prevention of pneumonia in acute leukemia by patient education, spirometry, and positive expiratory pressure: A randomized controlled trial.
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24262.
    PubMed     Text format     Abstract available


    November 2015
  109. KANTARJIAN H
    Acute Myeloid Leukemia- Major Progress over Four Decades, and Glimpses into the Future.
    Am J Hematol. 2015 Nov 24. doi: 10.1002/ajh.24246.
    PubMed     Text format    


  110. GAMBACORTI-PASSERINI C, Aroldi A, Cordani N, Piazza R, et al
    Chronic myeloid leukemia: Second-line drugs of choice.
    Am J Hematol. 2015 Nov 20. doi: 10.1002/ajh.24247.
    PubMed     Text format     Abstract available


  111. SHAH NP, Wallis N, Farber HW, Mauro MJ, et al
    Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
    Am J Hematol. 2015;90:1060-4.
    PubMed     Text format     Abstract available


    October 2015
  112. MORI S, Vagge E, le Coutre P, Abruzzese E, et al
    Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.
    Am J Hematol. 2015;90:910-4.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: